DIABETES Flashcards
What are the different types of Diabetes
- Type 1 and 2
- Gestational DM
- Neonatal Diabetes
- Diabetes caused by Cystic Fibrosis , pancreatitis , glucocorticosteriod ( Crushing Syndrome )
What are the clinical presentation of TYPE 1 DIABETES
Polydispia ( drink water )
Polyphagia ( hunger )
Polyuria ( increase urination)
weight loss
Clinical presentation for type 2 diabetes
increase weight
nocturia
Polydispia
Polyurea
What are the four different Criteria for Diagnosing DM
Hb A1C >= 6.5 %
Fasting (no food for the last 8 hrs) > 126mg/dl
OGTT >200mg/dl
RG > 200mg/dl
name and state is the MOA of GLP 1 Agonist and their side effect
laraglutide (Saxenda)
semaglutide (Ozempic)
dulaglutide (Trulicity)
MOA ; this is a harmone that is release from the intestin and bond to the receptors in the brain to slow down apatite , the liver to prevent the release of glucose , stomach to slow down gastric emptying ,and in the pancreases to releases insulin .
SE; injection site reaction , pancretites ,Diarreah ,BBW thyroid cancer .
Name the SGLT Antagonist and their MOA and side effects
INVOKANA (Canagliflozin) 300 mg tablet
JARDIANCE (empagliflozin ) 10mg and 20mg
FORXIGA (dapagliflozin)
they block the Na glucose transporter at the proximal tubules and prevent reabsorption of Glucose .
SE; increase thirst , dehydration , urinary infections .
Name the DDP4 inhibitors , there MOA and side effects
JANUVIA (siptagliptin)
ONGLYZA (SAXAgliptin)
TRADJENTA (LIGNAgliptin)
inhibit the enzyme DDP4 which intern prevent the break down of GLP1 .
SE
rare cases of Steven Johnson Syndrome
facial edema
Name the Thiazolidinediones , their MOA and side effects .
ACTOS (Pioglitazones )
AVANDIA (Rosiglitazone)
increase storage of fatty acid in adipose tissue thus decreases fatty acid in circulation cells are now more dippendent on glucose thus inhance insulin sensitivity in muscle , liver and fat tissues
SE cause peripheral edema thus contraindicated in stage 3 and 4 HF . Weight gain
Avandia cause an increase in triglycerides and LDL
Name the different sulfonylureas , MOA and SE
DIMICRON (glyclazide) ( RECLIDE)
GLYNASE(glyburide\glibenclamide)
AMYRYL (glimipiride) ( GLYREE)
GLUCOTROL (Glipizide)
MOA; close the K pump causes an increase of K inside the cell this cause depolarization of the cell which result in the influx of Ca irons in the cell which result in the release of insulin from the bata cells
hypoglycemia
Weight Gain
Rash
IG Problems
Name the Alpha Glucosidase inhibitors ,MOA, SE
PRECOSE( Acarbose)
GLENSET ( Miglitol)
a-Glucosidase is an enzyme that convert large sugar molecule in smaller molecules . there4 by inhibiting this may prolong Carbohydrate absorption .
Bloating abdominal discomfort and possible diarehha
what are the non Pharmalogical approach in treating Diabetes
- -Exercise at lease 150min /week
- - Healthy balanced diet
When education a patient about there diabetes what are some key point you need to tell them .
- -foot care
- -eye care
- -dental care
- -self monitoring glucose level
- -complication of diabetes
what are some of the key pints you need to consider when chosing a diabetic drug
–side effect of the drug
–the % A1C capability
–patient preferred root of administration
–how long the patient has diabetes -
What is
HYPERGLYCAEMIC HYPEROSMOLAR NONKETOTIC SYNDROME (HHNKS) and how is it treated
This is when Plasma glucose levels > 600mg/dl, minimal to no ketones.
Mainly in type two diabetes
Start IV fluids 0.9% Saline
Correction of any hypokalaemia
Continuous IV infusion of REGULAR Insulin (as long as serum K is ≥ 3.3 meq/L)
▪Bolus dose 0.1 units/kgIV,
▪Maintenance dose 0.1 units/kg/h/IV
▪When BG approach 200mg/dl, solns should be changed to Dextrose 5W/0.45% NaCL .
Blood glucose levels should be lowered slowly with hypotonic fluids
and low-dose insulin infusions
What is DIABETIC KETOACIDOSIS
(DKA)
And how is it treated
plasma glucose>250mg/dl but < 600mg/dl, positive urine and serum ketones, arterial PH<7.3, Na bicarbonate <15mEq/L
DKA requires immediate treatment:
▪ Start IV fluids 0.9% Saline
▪Correction of any hypokalaemia
▪Continuous IV infusion of REGULAR Insulin (as long as serum K is ≥ 3.3 meq/L)
▪Bolus dose 0.1 units/kgIV,
▪Maintenance dose 0.1 units/kg/h/IV
▪When BG approach 200mg/dl, solns should be changed to Dextrose 5W/0.45% NaCL . ( allow continuation of insulin therapy without causing hypoglycemia)